WHAT IS CLAIMED IS:

1. A use of IL-35 antagonist in preparing a pharmaceutical composition for treating cancer metastasis; wherein said pharmaceutical composition comprises said IL-35 antagonist and a pharmaceutically acceptable carrier;

   wherein said cancer is breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer, colon cancer, liver cancer, ovarian cancer, or oral cancer.

2. The use of claim 1, wherein said IL-35 antagonist is an antibody or antigen-binding fragment thereof, or a small molecule inhibitor.

3. The use of claim 2, wherein said antibody or antigen-binding fragment thereof binds to IL-35, EBI3, subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, , IL-12Rβ2, gp130/ IL-12Rβ2 heterodimer, IL-27Rα/ IL-12Rβ2 heterodimer, or a combination thereof.

4. The use of claim 2, wherein said IL-35 antagonist is a multispecific antibody or antigen-binding fragment.

5. The use of claim 2, wherein said IL-35 antagonist is a bispecific antibody or antigen-binding fragment that binds to two antigens selected from a group consisting of IL-35, Epstein-Barr-virus-induced gene3 (EBI3), subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, IL-12Rβ2, gp130/ IL-12Rβ2 heterodimer, and IL-27Rα/ IL-12Rβ2 heterodimer.

6. The use of claim 1, wherein said pharmaceutically acceptable carrier is water, PBS, salt solutions, gelatins, oils, alcohols, or a combination thereof.

7. A pharmaceutical composition for treating cancer metastasis of a subject had a primary cancer treatment, comprising:

   an IL-35 antagonist; and

   a pharmaceutically acceptable carrier;

wherein said cancer is breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer, colon cancer, liver cancer, ovarian cancer, or oral cancer.

8. The pharmaceutical composition of claim 7, wherein said IL-35 antagonist is an antibody or antigen-binding fragment thereof, or a small molecule inhibitor.

9. The pharmaceutical composition of claim 8, wherein said antibody or antigen-binding fragment thereof binds to IL-35, EBI3, subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, , IL-12Rβ2, gp130/ IL-12Rβ2 heterodimer, IL-27Rα/ IL-12Rβ2 heterodimer, or a combination thereof.

10. The pharmaceutical composition of claim 7, wherein said IL-35 antagonist is a multispecific antibody or antigen-binding fragment.

11. The pharmaceutical composition of claim 7, wherein said IL-35 antagonist is a bispecific antibody or antigen-binding fragment that binds to two antigens selected from a group consisting of IL-35, Epstein-Barr-virus-induced gene3 (EBI3), subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, , IL-12Rβ2, gp130/ IL-12Rβ2 heterodimer, and IL-27Rα/ IL-12Rβ2 heterodimer.

12. The pharmaceutical composition of claim 7, wherein said pharmaceutically acceptable carrier is water, PBS, salt solutions, gelatins, oils, alcohols, or a combination thereof.

13. The pharmaceutical composition of claim 7, further comprising a CSF1R antagonist.

14. The pharmaceutical composition of claim 13, wherein said CSF1R antagonist is an antibody or antigen-binding fragment thereof, a shRNA, a siRNA, a miRNA, or a small molecule inhibitor.

15. The pharmaceutical composition of claim 7, wherein said primary cancer

treatment is endocrine therapy, chemotherapy, radiotherapy, hormone therapy, surgery, gene therapy, thermal therapy, ultrasound therapy, or a combination thereof.

16. A kit for treating cancer metastasis of a subject having had a primary cancer treatment, comprising:

a first container comprising an IL-35 antagonist; and

a second container comprising a CSF1R antagonist;

wherein said cancer is breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer, colon cancer, pancreatic cancer, ovarian cancer, liver cancer, or oral cancer.

17. The kit of claim 16, wherein said IL-35 antagonist is an antibody or antigen-binding fragment thereof, or a small molecule inhibitor.

18. The kit of claim 17, wherein said antibody or antigen-binding fragment thereof binds to IL-35, EBI3, subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, IL-12Rβ2, gp130/ IL-12Rβ2 heterodimer, IL-27Rα/ IL-12Rβ2 heterodimer, or a combination thereof.

19. The kit of claim 16, wherein said CSF1R antagonist is an antibody or antigen-binding fragment thereof, a shRNA, a siRNA, a miRNA, or a small molecule inhibitor.

20. The kit of claim 16, wherein said IL-35 antagonist is a multispecific antibody or antigen-binding fragment.

21. The kit of claim 16, wherein said IL-35 antagonist is a bispecific antibody or antigen-binding fragment that binds to two antigens selected from a group consisting of IL-35, Epstein-Barr-virus-induced gene3 (EBI3), subunit P35 of IL-35, EBI3/P35 heterodimer, IL-35 receptor on cancer cells, IL-12Rβ2, gp130/

IL-12Rβ2 heterodimer, and IL-27Rα/ IL-12Rβ2 heterodimer.

22. The kit of claim 16, wherein said primary cancer treatment is endocrine therapy, chemotherapy, radiotherapy, hormone therapy, surgery, gene therapy, thermal therapy, ultrasound therapy, or a combination thereof.